LT1001 team praised by TFDA & MOEA

Lumosa Therapeutics received its second national award in two days. Just one day after receiving the 2015 National Innovation Award (12/25), Lumosa's LT1001 (Naldebain™, SDE) was recognized jointly-Drug Research and Development Science and Technology Bronze Award in the pharmaceutical category. The award was held to encourage innovative research and development in pharmaceutical industry, enhance the quality of clinical trials and manufacturing standards, and strengthen Taiwan’s competitiveness among global pharmaceutical technology industry. CEO Dr. Wendy Huang and Head of Pharmaceutical Development, Dr. David Chou, accepted the trophy and certificate from Ms. Yu-mei Chiang, Director-General of TFDA and Mr. Cheng-hua Lu, Deputy-Director, Industrial Development Bureau of the MOEA, on behalf of Lumosa Therapeutics. LT1001 features an extended release formulation which provides up to 7-day analgesic effect, low side effects, and low risk of addiction. The product is designed to effectively elevate patient quality of life and reduce burden of healthcare professionals. This second award reconfirmed the successful development program and the accomplishment of the Lumosa R&D team. Lumosa is looking forward to achieve the next milestones when LT1001 is approved for marketing and launched in the future.

Lumosa receives the National Innovation Award

Dr. Wendy Huang, CEO of Lumosa Therapeutics, received the 2015 National Innovation Award today (12/24) on behalf of Lumosa team at W Hotel, Taipei, from Mr. Jin-pyng Wang, the Speaker of the Taiwan Legislative Yuan (Congress), for the development of LT1001 (Naldebain™，SDE), the first long-acting intramuscular analgesic injection. LT1001 features an extended release formulation which provides up to 7-day analgesic effect, low side effects, and low risk of addiction. The product is designed to effectively elevate patient quality of life and reduce burden of healthcare professionals. This award not only recognized the development and the technical capabilities of Lumosa team, but also encouraged those who were involved in the project. Lumosa is looking forward to achieve another great milestone when LT1001 is approved for marketing in the future.

Lumosa out-licenses LT1001 to Taiwan

Signing of Exclusive Taiwanese Marketing Agreement for Lumosa’s LT1001, A Long Acting Injection for Moderate to Severe Pain   Lumosa Therapeutics announced the signing of an exclusive agreement with InteRx Biomedical Co. Ltd. (InteRx), a subsidiary of AMED Co. Ltd. (AMED) to commercialize LT1001, a long-acting injectable for moderate to severe pain, in Taiwan. This licensing agreement is the third milestone for LT1001 in 2015 after successfully completed a Phase III clinical study last August and the NDA submission to the TFDA last September. Out-licensing of LT1001 is in progress in several other markets.

Lumosa attends STAIRS IX

PAK01 selected as top 10% abstract by AHA

PAK01: A Synthesized Small Molecule That Enhances Reperfusion, Neuroprotection and Avoids Hemorrhagic Transformation in Rodent Models of Thromboembolic Stroke, a paper about LT-3001 presented at the 2014 International Stroke Conference, San Diego, USA, was selected as the top 10% abstracts, and invited to the Best of AHA Specialty Conference Poster Sessions on November 17, 2014, at McCormick Convention Center, Chicago, IL, USA. The International Stroke Conference, a premier scientific meeting organized by the American Heart Association, is the world s largest meeting for the basic, clinical and translational sciences and the treatments of cerebrovascular disease. More than 900 presentations of recent scientific work in cerebrovascular disease and stroke were introduced over a two and a half day conference.